CLU's role in Alzheimer's disease pathogenesis
Official title: The role of CLU in molecular pathogenesis of Alzheimers disease
Funded at Translational Genomics Research Inst · NIH-11622617 · Data updated 2026-11-12
Researchers are studying how the CLU gene may drive brain changes in Alzheimer's disease and how targeting CLU could lead to safer treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Translational Genomics Research Inst NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | September 22, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $798,749 |
| NIH project number | 1R56AG100407-01 |
| Project ID | NIH-11622617 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with or at risk for Alzheimer's disease who have amyloid-related pathology and are candidates for future disease-modifying therapies.
✕Less likely to help
Individuals without Alzheimer’s pathology or those not eligible for amyloid-targeting therapies may not benefit from this research findings.
What this research studies
This project uses a new humanized mouse model to examine how CLU expression in brain cells affects amyloid buildup and vascular side effects. By comparing CLU produced by astrocytes to CLU in amyloid plaques, the team aims to identify when and how interventions might clear amyloid without causing brain bleed risks. The work could guide development of safer, more precise therapies for people with Alzheimer’s disease and related cognitive decline.
Why it matters
Potential benefit: If successful, this research could lead to safer, targeted treatments that reduce amyloid in the brain with fewer vascular side effects for people with Alzheimer's disease.
How similar studies have gone: Previous studies using humanized models and APOE/CLU-linked approaches have shown promise in understanding amyloid dynamics, though this exact CLU-focused strategy is relatively novel.
Where this research is happening
-
Translational Genomics Research Inst
Phoenix, United States Active
Researchers
- Principal investigator: Fryer, John David — Translational Genomics Research Inst
- Study coordinator: Fryer, John David
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Cognitive SuperAging: Exploring why some octogenarians stay sharp in memory
This NIH grant studies why a small group of people aged 80+ keep memory skills as good as much younger people, hoping to understand how to protect memory as we age.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.